长春高新子公司绒促卵泡激素αN02注射液在境内获批上市

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of its drug, FSH-CTP injection, in China [1] Group 1: Company Information - The approved product is a long-acting recombinant human follicle-stimulating hormone (FSH-CTP) injection, developed using genetic engineering technology [1] - FSH-CTP is designed to replace the traditional 7-day regimen of follicle-stimulating hormone injections with a single subcutaneous injection [1] - The product falls under the category of therapeutic biological products, classified as type 3.2 [1] Group 2: Industry Context - The approval of FSH-CTP injection represents a significant advancement in reproductive health treatments, potentially improving patient compliance and treatment outcomes [1] - The use of CHO cell expression technology for drug development highlights the ongoing innovation within the biopharmaceutical industry in China [1]